{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:17:23Z","timestamp":1781871443662,"version":"3.54.5"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00120","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:13:11Z","timestamp":1580861591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Macrophages\/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain"],"prefix":"10.3389","volume":"11","author":[{"given":"Dayana","family":"Herrera-Rios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf S.","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Teuber-Hanselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pierscianek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Schimming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Klode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Reifenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Felsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Brors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Reifenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Helfrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science."},{"key":"B3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.it.2016.01.006","article-title":"Type I\/II interferon balance in the regulation of brain physiology and pathology","volume":"37","author":"Deczkowska","year":"2016","journal-title":"Trends Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.3390\/ijms19010089","article-title":"The dark side of IFN-gamma: its role in promoting cancer immunoevasion","volume":"19","author":"Mojic","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1096\/fasebj.5.11.1907934","article-title":"Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism","volume":"5","author":"Taylor","year":"1991","journal-title":"FASEB J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejca.2017.01.011","article-title":"The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy","volume":"76","author":"Brochez","year":"2017","journal-title":"Eur J Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J Immunother Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3109\/08820139.2012.689405","article-title":"Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance","volume":"41","author":"Johnson","year":"2012","journal-title":"Immunol Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.4049\/jimmunol.0900986","article-title":"IDO activates regulatory T cells and blocks their conversion into Th17-like T cells","volume":"183","author":"Baban","year":"2009","journal-title":"J Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1126\/science.1073514","article-title":"Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase","volume":"297","author":"Munn","year":"2002","journal-title":"Science."},{"key":"B14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/bjd.13100","article-title":"Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?","volume":"171","author":"Chevolet","year":"2014","journal-title":"Br J Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ejca.2011.09.007","article-title":"Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients","volume":"48","author":"Speeckaert","year":"2012","journal-title":"Eur J Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.neo.2017.12.002","article-title":"A longitudinal analysis of IDO and PDL1 expression during immune- or targeted therapy in advanced melanoma","volume":"20","author":"Kr\u00e4henb\u00fchl","year":"2018","journal-title":"Neoplasia."},{"key":"B17","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/S0959-8049(16)30312-4","article-title":"511 Updated results from a phase 1\/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma","volume":"51","author":"Gibney","year":"2015","journal-title":"Eur J Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"mdx377","DOI":"10.1093\/annonc\/mdx377.001","article-title":"1214OEpacadostat plus pembrolizumab in patients with advanced melanoma: phase 1 and 2 efficacy and safety results from ECHO-202\/KEYNOTE-037","volume":"28","author":"Hamid","year":"2017","journal-title":"Ann Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science."},{"key":"B22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/EDBK_200819","article-title":"New era in the management of melanoma brain metastases","author":"Tawbi","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1756-9966-30-10","article-title":"Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center","volume":"30","author":"Fabi","year":"2011","journal-title":"J Exp Clin Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1200\/JCO.2011.40.6983","article-title":"Identifying early melanomas at higher risk for metastases","volume":"30","author":"Balch","year":"2012","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1007\/s00330-013-2857-3","article-title":"Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not?","volume":"23","author":"Gramsch","year":"2013","journal-title":"Eur Radiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.clineuro.2013.03.019","article-title":"Intracerebral metastases of malignant melanoma and their recurrences\u2013a clinical analysis","volume":"115","author":"Miller","year":"2013","journal-title":"Clin Neurol Neurosurg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s11912-013-0335-3","article-title":"Melanoma brain metastases: an unmet challenge in the era of active therapy","volume":"15","author":"Gorantla","year":"2013","journal-title":"Curr Oncol Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin."},{"key":"B31","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1084\/jem.20142290","article-title":"A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules","volume":"212","author":"Aspelund","year":"2015","journal-title":"J Exp Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1038\/srep04422","article-title":"Immune privilege of the CNS is not the consequence of limited antigen sampling","volume":"4","author":"Harris","year":"2014","journal-title":"Sci Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20102657","article-title":"Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain","volume":"208","author":"Anandasabapathy","year":"2011","journal-title":"J Exp Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/ncponc1183","article-title":"CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS","volume":"5","author":"Hodi","year":"2008","journal-title":"Nat Clin Pract Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3978\/j.issn.2304-3865.2015.06.03","article-title":"The inflammatory microenvironment in brain metastases: potential treatment target?","volume":"4","author":"Berghoff","year":"2015","journal-title":"Chin Clin Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"40836","DOI":"10.18632\/oncotarget.5696","article-title":"Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1\/PD-L1 immune checkpoints in human brain metastases","volume":"6","author":"Harter","year":"2015","journal-title":"Oncotarget."},{"key":"B38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/his.12537","article-title":"Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases","volume":"66","author":"Berghoff","year":"2015","journal-title":"Histopathology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-17-0114","article-title":"Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions","volume":"23","author":"Nishino","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"25216","DOI":"10.18632\/oncotarget.25393","article-title":"Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile","volume":"9","author":"Meireson","year":"2018","journal-title":"Oncotarget."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti\u2013programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.molimm.2011.08.017","article-title":"IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive","volume":"49","author":"Godin-Ethier","year":"2011","journal-title":"Mol Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/vaccines3030703","article-title":"The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity","volume":"3","author":"Mbongue","year":"2015","journal-title":"Vaccines."},{"key":"B47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.it.2005.12.006","article-title":"The immunoregulatory role of IDO-producing human dendritic cells revisited","volume":"27","author":"Terness","year":"2006","journal-title":"Trends Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0002-9610(78)90171-X","article-title":"Metastatic pattern of malignant melanoma. A study of 216 autopsy cases","volume":"135","author":"Patel","year":"1978","journal-title":"Am J Surg."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer."},{"key":"B50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Cancer."},{"key":"B51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell."},{"key":"B55","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/0008-5472.CAN-18-1805","article-title":"A Blazing landscape: neuroinflammation shapes brain metastasis","volume":"79","author":"Doron","year":"2019","journal-title":"Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10555-012-9373-9","article-title":"The metastatic niche and stromal progression","volume":"31","author":"Sleeman","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11060-015-1977-9","article-title":"Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab","volume":"126","author":"Frenard","year":"2016","journal-title":"J Neurooncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-12-3080","article-title":"Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control","volume":"19","author":"Robert","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"9501","DOI":"10.1200\/JCO.2019.37.15_suppl.9501","article-title":"Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)","volume":"37","author":"Tawbi","year":"2019","journal-title":"J Clin Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","article-title":"A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC)","volume":"35","author":"Long","year":"2017","journal-title":"J Clin Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1084\/jem.20091846","article-title":"Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma","volume":"207","author":"Helfrich","year":"2010","journal-title":"J Exp Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1002\/j.1460-2075.1991.tb04878.x","article-title":"Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein\/ret fusion gene","volume":"10","author":"Iwamoto","year":"1991","journal-title":"EMBO J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","article-title":"Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (Atezolizumab) in advanced solid tumors","volume":"25","author":"Jung","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-019-0562-8","article-title":"Phase 1\/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma","volume":"7","author":"Gibney","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B65","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12967-018-1595-3","article-title":"Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?","volume":"16","author":"Botticelli","year":"2018","journal-title":"J Transl Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00262-018-2190-4","article-title":"Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"67","author":"Brown","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10585-012-9510-4","article-title":"Characterization of the inflammatory response to solid cancer metastases in the human brain","volume":"30","author":"Berghoff","year":"2013","journal-title":"Clin Exp Metastasis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","article-title":"Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases","volume":"5","author":"Berghoff","year":"2016","journal-title":"Oncoimmunology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/0008-5472.CAN-17-1720","article-title":"T-cell densities in brain metastases are associated with patient survival times and diffusion tensor MRI changes","volume":"78","author":"Zakaria","year":"2018","journal-title":"Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1046\/j.1365-2249.1998.00702.x","article-title":"Interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD","volume":"114","author":"Sasiain","year":"1998","journal-title":"Clin Exp Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-07-4144","article-title":"Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival","volume":"14","author":"Ino","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3389\/fimmu.2019.01713","article-title":"Microenvironmental regulation of tumor progression and therapeutic response in brain metastasis","volume":"10","author":"Schulz","year":"2019","journal-title":"Front Immunol."},{"key":"B74","first-page":"2592","article-title":"Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma","volume":"62","author":"Wischhusen","year":"2002","journal-title":"Cancer Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/neuonc\/now241","article-title":"Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)","volume":"19","author":"Soffietti","year":"2017","journal-title":"Neuro Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/EdBook_AM.2013.33.399","article-title":"Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases","author":"Ramakrishna","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"B77","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2217\/imt-2018-0156","article-title":"Re-education of macrophages as a therapeutic strategy in cancer","volume":"11","author":"Kowal","year":"2019","journal-title":"Immunotherapy."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:13:16Z","timestamp":1580861596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2020.00120"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00120","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]},"article-number":"120"}}